Advertisement

Current Cardiology Reports

, 15:321 | Cite as

Platelet Function Monitoring and Clopidogrel

  • Andrew R. Harper
  • Matthew J. PriceEmail author
New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)
Part of the following topical collections:
  1. Topical Collection on New Therapies for Cardiovascular Disease

Abstract

Antiplatelet therapy with aspirin and a platelet P2Y12 receptor antagonist reduces thrombotic and ischemic events after percutaneous coronary intervention and acute coronary syndrome. The platelet inhibitory effect of the thienopyridine clopidogrel varies widely among individuals, and high on-treatment platelet reactivity has been associated with a substantial hazard for post-PCI cardiovascular events, including stent thrombosis. The clinical availability of ex vivo methods to measure the antiplatelet effect of P2Y12 antagonists raises the possibility that incorporating platelet function testing into clinical practice could facilitate a stratified and efficient approach to antiplatelet therapy following PCI, although data from definitive randomized trials supporting a routine approach are currently lacking.

Keywords

Clopidogrel Platelet function testing Monitoring Thienopyridine 

Notes

Conflicts of interest

A.R. Harper: none; M.J. Price: has been a consultant for AstraZeneca, Daiichi-Sankyo/Eli Lilly and Co., Accumetrics, Inc., Janssen Pharmaceuticals, Medicure, Merck, The Medicines Company, and BMS/Sanofi; and has received payment for development of educational presentations including service on speakers’ bureaus for AstraZeneca, DSI/Lilly, and modest equity interest in Iverson Genetics.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med. 1998;339:1665–71.Google Scholar
  2. 2.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.Google Scholar
  3. 3.
    Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.Google Scholar
  4. 4.
    Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20.Google Scholar
  5. 5.
    Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294:1224–32.Google Scholar
  6. 6.
    Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179–89.Google Scholar
  7. 7.
    Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982–8.Google Scholar
  8. 8.
    Price MJ, Tantry US, Gurbel PA. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Rev Cardiovasc Med. 2011;12:1–12.Google Scholar
  9. 9.
    Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27:1166–73.Google Scholar
  10. 10.
    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.Google Scholar
  11. 11.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel vs clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.Google Scholar
  12. 12.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor vs clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.Google Scholar
  13. 13.
    • Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation. 2009;119:2625–32. This article summarizes the different platelet function tests that can be used to measure the antiplatelet effect of P2Y12 antagonists.PubMedCrossRefGoogle Scholar
  14. 14.
    Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther. 2006;319:1467–76.Google Scholar
  15. 15.
    Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92–9.Google Scholar
  16. 16.
    Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(66):e69–16.Google Scholar
  17. 17.
    Payne CD, Li YG, Small DS, Ernest CS, 2nd, Farid NA, Jakubowski JA, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared with high-dose clopidogrel. J Cardiovasc Pharmacol. 2007;50:555–62.Google Scholar
  18. 18.
    Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2428–36.Google Scholar
  19. 19.
    Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30:1744–52.Google Scholar
  20. 20.
    Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–7.Google Scholar
  21. 21.
    •• Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57. A seminal study using genome wide association study to demonstrate that the CYPC19 locus is the key genetic determinant of clopidogrel response variability.Google Scholar
  22. 22.
    Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) Study. J Am Coll Cardiol. 2012;59:1928–37.Google Scholar
  23. 23.
    Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost. 2010;8:1685–93.Google Scholar
  24. 24.
    Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57:2474–83.Google Scholar
  25. 25.
    Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn H-P, et al. Impact of Cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427–34.Google Scholar
  26. 26.
    Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821–30.Google Scholar
  27. 27.
    Cayla G, Hulot J-Sb, O'Connor SA, Pathak A, Scott SA, Gruel Y. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306:1765–74.Google Scholar
  28. 28.
    Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008;52:531–3.Google Scholar
  29. 29.
    Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, et al. Cigarette smoking is associated with a dose–response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv. 2012;5:293–300.Google Scholar
  30. 30.
    Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–13.PubMedCrossRefGoogle Scholar
  31. 31.
    Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008;52:1557–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009;103:1339–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.Google Scholar
  34. 34.
    Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–8.PubMedGoogle Scholar
  36. 36.
    van Werkum JW, Kleibeuker M, Postma S, Bouman HJ, Elsenberg EH, Ten Berg JM, et al. A comparison between the Plateletworks-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol. 2008;140:123–6.Google Scholar
  37. 37.
    Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006;28:315–22.PubMedCrossRefGoogle Scholar
  38. 38.
    Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005;3:85–92.PubMedCrossRefGoogle Scholar
  39. 39.
    Golanski J, Pluta J, Baraniak J, Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists–in vitro experience. Clin Chem Lab Med. 2004;42:25–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007;5:1839–47.Google Scholar
  41. 41.
    Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, et al. Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J. 2009;0:e1–9.Google Scholar
  42. 42.
    •• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(12):919–33. This article summarizes the observational studies linking clopidogrel response variability to clinical outcomes after PCI, and proposes specific cut-offs for the clinical identification of at-risk patients.Google Scholar
  43. 43.
    • Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim H-S, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58:1945–54. This study presents the largest sample size of patient-level data yet reported to examine the relationship between on-treatment reactivity and outcomes after PCI.Google Scholar
  44. 44.
    Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a verifynow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124:1132–7.Google Scholar
  45. 45.
    Stone GW. Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES): a large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after des implantation. Proceedings of the Transcatheter Cardiovascular Therapeutics; San Francisco, CA. 2011.Google Scholar
  46. 46.
    Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost. 2010;103:1128–35.PubMedCrossRefGoogle Scholar
  47. 47.
    • Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51:1404–11. This is the first, proof-of-principle, randomized study to demonstrate a potential benefit of platelet function-guided antiplatelet therapy in PCI patients.Google Scholar
  48. 48.
    Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat-Bonello C, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol. 2009;103:5–10.Google Scholar
  49. 49.
    Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation. 2009;119:3215–22.Google Scholar
  50. 50.
    Campo G, Fileti L, de Cesare N, Meliga E, Furgieri A, Russo F, et al. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3 T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol. 2010;56:1447–55.Google Scholar
  51. 51.
    •• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105. This article presents the results of the first large, multicenter, randomized trial of platelet function testing in patients undergoing PCI.Google Scholar
  52. 52.
    Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study. J Am Coll Cardiol. 2012;59:2159–64.Google Scholar
  53. 53.
    Aradi D, Komocsi A, Price MJ, Cuisset T, Ari H, Hazarbasanov D, et al. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol. 2012. doi: 10.1016/j.ijcard.2012.05.100.
  54. 54.
    Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE, Jr., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2012;126:875–910.Google Scholar
  55. 55.
    Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52:1693–701.PubMedCrossRefGoogle Scholar
  56. 56.
    Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE, Jr., Ettinger SM, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/ non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation. 2011;123:2022–60.Google Scholar
  57. 57.
    Price MJ, Coleman JL, Steinhubl SR, Wong GB, Cannon CP, Teirstein PS. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol. 2008;102:790–5.PubMedCrossRefGoogle Scholar
  59. 59.
    • Price MJ, Walder JS, Baker BA, Heiselman DE, Jakubowski JA, Logan DK, et al. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the Recovery Trial. J Am Coll Cardiol. 2012;59:2338–43. This randomized multicenter pharmacodynamic study describes the time course of platelet recovery after clopidogrel discontinuation.Google Scholar
  60. 60.
    Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–82.Google Scholar
  61. 61.
    Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to cabg (target-cabg) study. Circ Cardiovasc Interv. 2012;5:261–9.Google Scholar
  62. 62.
    Price MJ, Angiolillo DJ. Platelet inhibitor agents. In: Topol EJ, Teirstein PS, editors. Textbook of Interventional Cardiology, 6th ed. Philadelphia: Saunders; 2012.Google Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Faculty of Medical SciencesNewcastle UniversityNewcastle upon TyneUK
  2. 2.Scripps Clinic and Scripps Translational Science InstituteLa JollaUSA

Personalised recommendations